bioRxiv Science⌕ Search

Biology subjects

Lema, K.

Publications and source records attributed to Lema, K..

2 recordsLinked to original sources

Mapping the Transcriptional Landscape of Drug Responses in Primary Human Cells Using High-Throughput DRUG-seq

To advance our understanding of drug action in physiologically-relevant systems, we developed a high-throughput transcriptomic atlas of compound responses in primary human cell types. Leveraging the scalable and cost-effective Digital RNA with the pertUrbation of Genes (DRUG-seq) assay, we profiled gene expression responses to 89 pharmacologically-active compounds across six concentrations in four distinct primary cell types: aortic smooth muscle cells (AoSMCs), skeletal muscle myoblasts (SkMMs), dermal fibroblasts, and melanocytes. Through rigorous quality control and normalization, we generated reproducible and cell type-resolved transcriptomic signatures, enabling the discovery of both shared and divergent regulatory programs. This dataset revealed core cellular responses, such as brefeldin A-mediated ER stress across all cell types, as well as lineage-specific effects, including dexamethasone-induced hypoxia signaling in AoSMCs, complex inflammatory responses linked to epithelial-to-mesenchymal transition pathways in SkMMs, TGF-{beta}-modulated states in fibroblasts, and dabrafenib-driven transcriptional shifts towards quiescence in melanocytes. By integrating systematic perturbations with primary models, this dataset serves as a resource for building systems-level models of drug response and mechanism. Ultimately, we aim to accelerate predictive pharmacology by enabling high-throughput data generation grounded in human biology and readily usable by artificial intelligence models.

systems biology↗

The ATLAS™ screening assay reveals distinct CD4+ and CD8+ SARS-CoV-2 antigen response profiles which have implications to Omicron cellular immunity

The emergence of SARS-CoV-2 variants are a persistent threat to the efficacy of currently developed prophylactic vaccines and therapeutic antibodies. These variants accumulate mutations in the spike protein which encodes the epitopes necessary for neutralizing antibody binding. Moreover, emerging evidence suggest that robust antibody responses are insufficient to prevent severe disease and long-lasting viral immunity requires T cells. Thus, understanding how the T cell antigen landscape evolves in the context of these emerging variants remains crucial. T cells responses are durable and recognize a wider breadth of epitopes reducing the possibility of immune escape through mutation. Here, we deploy the ATLAS assay which identifies CD4+ and CD8+ T cell antigens by utilizing the endogenous HLA class-I and class-II peptide processing pathways. Profiling of T cells from exposed and unexposed donors revealed rich and complex patterns which highlighted the breadth of antigenic potential encoded in SARS-CoV-2. ATLAS revealed several common or frequent antigenic regions as well as an abundance of responses in the unexposed cohort potentially the result of pre-exposure to related coronaviruses. ORF10 was a common CD4+ response in the unexposed cohort while spike was identified as a common and frequent target in both cohorts. Moreover, the spike response profiles allowed us to accurately predict the impact of Omicron spike mutations. This analysis could thus be applied to study the impact of future emerging VOCs.

immunology↗